Morimatsu has recently signed a new order with a leading international vaccine company to undertake process system projects for their new plants in both Asia and Europe. Morimatsu has already undertaken several projects in China carried on by the customer earlier, and this time we participated in the tender as the only Chinese supplier and successfully won the new order, which is the beginning of a global cooperation based on the previous successful project experience.

The new plant for this project will be built to a diversified vaccine platform with the capability to produce cell culture-based vaccines and mRNA vaccines. The new plant is dedicated to producing large quantities of vaccines for the global market in order to quickly respond to the risk of future pandemics.

Based on the good cooperation with customers and the common pursuit of high-quality equipment and engineering projects, Morimatsu has gradually gained strengths in the accompany with the head pharmaceutical companies:

1. Abundant experience in core equipment and engineering project management in different regions around the world

Since 2002, Morimatsu has been supplying high quality core equipment to overseas customers. With our superb project export capabilities, we have by now supplied core equipment, process systems and modular plants to many leading companies in over 40 countries worldwide.

2. The familiarity with global laws and regulations and the compliance to GMP regulations in different countries

Morimatsu has accumulated a wealth of experience and is familiar with the standards and regulations of mainstream countries and regions around the world. Responding to the GMP regulations of different countries is the key to exporting pharmaceutical equipment. Morimatsu keeps up with the latest global GMP trends and has professional knowledge and sufficient experience in interpreting and meeting the GMP of WHO, European Medicines Agency (EMA) and US Food and Drug Administration (FDA). Currently, we have numerous cases that have successfully passed GMP inspections by the European Medicines Agency and the US Food Surveillance Agency.

3. Morimatsu people always commits themselves to the spirit of craftsmanship - attention to detail, the pursuit of perfection

The master in international advanced design concepts and expertise is the key to ensure advanced, reliable systems and improve efficiency, product quality and safety. Today, Morimatsu's quality has been highly evaluated and recognized by foreign customers and many international giant companies have regarded Morimatsu as a long-term global partner.

4. The world's leading modular solution provider

Morimatsu guarantees faster project delivery, lower risk, predictable project implementation and great flexibility, bringing the "power of certainty" to our clients and better demonstrating our global delivery capabilities.

Looking back, Morimatsu has continued to cooperate with international headline companies, including partnerships with four major vaccine companies dating back as far as 2005. Since then, international cooperation began to flow. Up to now, Morimatsu has maintained cooperation with the four major vaccine giants for more than ten years, and the products are not only sent to China, but also exported to Singapore, Australia, New Zealand, France and many other countries.

Morimatsu firmly grasps every coming opportunity and we are committed to providing our customers with the highest quality products and the most attentive service. The growing partnership with these giant companies from developed countries in Europe and North America has also enabled Morimatsu to move further and steadily as a global supplier.

About Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd.

Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd (Stock Code: 2155.HK) is a wholly-owned subsidiary of Morimatsu International Holdings Company Limited. Morimatsu, founded in Japan and taken root in China, has developed into a multi-national company that embraces globalization, masters core technology, and gains rich experience from project implementation in diverse fields including core equipment, process systems, and engineering solutions. The company has built advanced manufacturing base in China, established affiliates in Sweden, the United States, India, and Italy, built an efficient professional globalization team, and delivered a variety of products and services to more than 40 countries and regions.

Forward-Looking Statements

The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of “predicted”, “believed”, “forecast”, “planned” and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our company undertakes no obligation to constantly revise such predicted statements.

Forward-looking statements are based on our company management’s current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guaranties of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.